CN101616665B - 可用于治疗2型糖尿病的组合物 - Google Patents

可用于治疗2型糖尿病的组合物 Download PDF

Info

Publication number
CN101616665B
CN101616665B CN2007800518413A CN200780051841A CN101616665B CN 101616665 B CN101616665 B CN 101616665B CN 2007800518413 A CN2007800518413 A CN 2007800518413A CN 200780051841 A CN200780051841 A CN 200780051841A CN 101616665 B CN101616665 B CN 101616665B
Authority
CN
China
Prior art keywords
carnitine
acid
simvastatin
alkanoyl
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800518413A
Other languages
English (en)
Chinese (zh)
Other versions
CN101616665A (zh
Inventor
F·加埃塔尼
A·瓦玛尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Co ltd
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101616665A publication Critical patent/CN101616665A/zh
Application granted granted Critical
Publication of CN101616665B publication Critical patent/CN101616665B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2007800518413A 2007-02-27 2007-11-20 可用于治疗2型糖尿病的组合物 Expired - Fee Related CN101616665B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103137 2007-02-27
EP07103137.1 2007-02-27
PCT/EP2007/062545 WO2008104239A1 (en) 2007-02-27 2007-11-20 Composition useful for the treatment of type 2 diabetes

Publications (2)

Publication Number Publication Date
CN101616665A CN101616665A (zh) 2009-12-30
CN101616665B true CN101616665B (zh) 2013-03-27

Family

ID=38093451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800518413A Expired - Fee Related CN101616665B (zh) 2007-02-27 2007-11-20 可用于治疗2型糖尿病的组合物

Country Status (16)

Country Link
US (2) US20100029759A1 (enExample)
EP (1) EP2124925B1 (enExample)
JP (2) JP5697337B2 (enExample)
KR (1) KR101699430B1 (enExample)
CN (1) CN101616665B (enExample)
AU (1) AU2007348123B2 (enExample)
BR (1) BRPI0721333A8 (enExample)
CA (1) CA2678746C (enExample)
EA (1) EA016855B1 (enExample)
ES (1) ES2676529T3 (enExample)
IL (1) IL200192A (enExample)
MX (1) MX2009008873A (enExample)
PL (1) PL2124925T3 (enExample)
PT (1) PT2124925T (enExample)
SG (1) SG177993A1 (enExample)
WO (1) WO2008104239A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104239A1 (en) * 2007-02-27 2008-09-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of type 2 diabetes
US12697339B2 (en) * 2023-04-12 2026-08-04 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation
KR20260004765A (ko) * 2024-07-02 2026-01-09 건국대학교 글로컬산학협력단 스타틴이 결합된 담즙산을 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
US20020061301A1 (en) * 1998-05-15 2002-05-23 Olga Bandman Human carbohydrate metabolism enzymes
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
HUP0201597A3 (en) * 1999-06-08 2003-04-28 Sigma Tau Ind Farmaceutiche S Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
US20080102138A1 (en) * 2006-06-21 2008-05-01 Bieley Harlan C Replacement of Vitamins, Minerals and Neurotransmitter Losses from Tobacco Smoking
WO2008104239A1 (en) * 2007-02-27 2008-09-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of type 2 diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Francesco Brescia, et al.Effects of Combined Treatment with Simvastatin and L-Carnitine on Triglyceride Levels in Diabetic Patients with Hyperlipidaemia.《Clin Drug Invest》.2002,第22卷(第S1期),23-28. *
Vincenzo Solfrizzi, et al..Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.《Atherosclerosis》.2006,第188卷455-461. *

Also Published As

Publication number Publication date
EA200970798A1 (ru) 2010-04-30
PT2124925T (pt) 2018-07-12
JP2010519333A (ja) 2010-06-03
KR101699430B1 (ko) 2017-01-24
EA016855B1 (ru) 2012-08-30
AU2007348123B2 (en) 2013-01-17
KR20090115939A (ko) 2009-11-10
BRPI0721333A8 (pt) 2017-12-26
IL200192A (en) 2015-06-30
BRPI0721333A2 (pt) 2014-02-25
CA2678746C (en) 2018-05-01
IL200192A0 (en) 2010-04-15
JP5697337B2 (ja) 2015-04-08
WO2008104239A1 (en) 2008-09-04
PL2124925T3 (pl) 2018-09-28
JP2014040442A (ja) 2014-03-06
US20100029759A1 (en) 2010-02-04
CA2678746A1 (en) 2008-09-04
AU2007348123A1 (en) 2008-09-04
US20150045424A1 (en) 2015-02-12
MX2009008873A (es) 2009-08-28
EP2124925A1 (en) 2009-12-02
EP2124925B1 (en) 2018-06-27
SG177993A1 (en) 2012-02-28
HK1135030A1 (en) 2010-05-28
CN101616665A (zh) 2009-12-30
ES2676529T3 (es) 2018-07-20

Similar Documents

Publication Publication Date Title
US8853229B2 (en) Composition containing statins and omega-3 fatty acids
AU741363B2 (en) Composition comprising l-carnitine or an alkanoyl L-carnitine and long-chain alkanols
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
CA2678746C (en) Composition useful for the treatment of type 2 diabetes
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
AU2008228192B2 (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
CN101677983B (zh) 用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物
HK1135030B (en) Composition useful for the treatment of type 2 diabetes
EP2361092A1 (en) Health care
WO2023212091A1 (en) Novel ketone ester compounds
HK1028547B (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135030

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135030

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171205

Address after: Milan Italy

Patentee after: Alpha Sigg Ma Co.

Address before: Rome Italy

Patentee before: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Milan Italy

Patentee after: Alpha sigma Co.,Ltd.

Address before: Milan Italy

Patentee before: Alpha Sigg Ma Co.

CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Bologna, Italy

Patentee after: Alpha sigma Co.,Ltd.

Address before: Milan Italy

Patentee before: Alpha sigma Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327